CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality

Phase 3

Withdrawn

Conditions: Restoration of Function to CVADs

Interventions: Drug: CUSA-081

First Posted Date: 2019-06-20

Last Posted Date: 2022-04-15

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Registration Number: NCT03992443

Locations: 🇧🇬
Chiesi Investigational site, Stara Zagora, Bulgaria
🇭🇺
Chiesi investigational site, Székesfehérvár, Hungary
🇧🇬
Chiesi Investigational Site, Razgrad, Bulgaria

and more 1 locations

Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence

Not Applicable

Completed

Conditions: Asthma

Interventions: Behavioral: Marketed experience application on adherence

First Posted Date: 2019-05-15

Last Posted Date: 2021-07-01

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 160

Registration Number: NCT03951714

Locations: 🇬🇧
Barlow Medical Centre, Manchester, United Kingdom

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment D
Drug: Treatment F
Drug: Treatment C
Drug: Treatment E

First Posted Date: 2019-05-08

Last Posted Date: 2020-07-22

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 30

Registration Number: NCT03942666

Locations: 🇧🇪
SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
Drug: Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo

First Posted Date: 2019-03-25

Last Posted Date: 2024-11-25

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 750

Registration Number: NCT03888131

Locations: 🇨🇳
Site 15633 - Tianjin Haihe Hospital, Tianjin, Tianjin, China
🇨🇳
Site 15642 - Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
🇨🇳
Site 15639 -The second Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China

and more 50 locations

Registry Study of Revcovi Treatment in Patients With ADA-SCID

Completed

Conditions: Adenosine Deaminase Severe Combined Immunodeficiency

Interventions: Biological: elapegademase-lvlr

First Posted Date: 2019-03-18

Last Posted Date: 2024-11-15

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 32

Registration Number: NCT03878069

Locations: 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 11 locations

PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

Interventions: Drug: Placebo
Drug: Therapeutic Dose 2
Drug: Supra-therapeutic Dose
Drug: Therapeutic Dose 1

First Posted Date: 2019-03-01

Last Posted Date: 2021-10-22

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 32

Registration Number: NCT03859414

Locations: 🇬🇧
Richmond Pharmacology Ltd, London, Tooting, United Kingdom

Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients

Phase 1

Terminated

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

Interventions: Drug: Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide

First Posted Date: 2019-01-07

Last Posted Date: 2022-05-06

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 19

Registration Number: NCT03795350

Locations: 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, United Kingdom

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Phase 3

Active, not recruiting

Conditions: Fabry Disease

Interventions: Drug: pegunigalsidase alfa

First Posted Date: 2018-08-03

Last Posted Date: 2024-10-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 29

Registration Number: NCT03614234

Locations: 🇺🇸
Renal Disease Research Institute, LLC, Dallas, Texas, United States
🇩🇰
Medical Endocrinology PE 2132, Rigshospitalet, Copenhagen, Denmark
🇺🇸
UAB Medicine, Birmingham, Alabama, United States

and more 11 locations

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Phase 3

Terminated

Conditions: Catheter Occlusion
Thrombosis

Interventions: Drug: CUSA-081
Drug: Placebo
Drug: Alteplase

First Posted Date: 2018-07-20

Last Posted Date: 2024-08-23

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 462

Registration Number: NCT03594175

Locations: 🇷🇴
Chiesi Invesitgational Site, Cluj-Napoca, Romania
🇺🇸
Einspahr, Topeka, Kansas, United States
🇪🇸
Chiesi Investigational Site, Sevilla, Spain

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF 5993 DPI
Drug: CHF5993 pMDI
Drug: CHF 1535 pMDI
Drug: Placebo pMDI
Drug: Placebo DPI

First Posted Date: 2018-07-18

Last Posted Date: 2021-04-12

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 366

Registration Number: NCT03590379

Locations: 🇧🇬
Medical Center Convex EOOD, Sofia, Bulgaria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy